Healthcare technology firm BTG has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Ekos Control Unit 4.0 to treat blood clots and restore blood flow.
The system includes an ultrasound device that uses acoustic pulses to dissolve blood clots and restore blood flow in patients with pulmonary embolism (PE), deep vein thrombosis (DVT), and peripheral arterial occlusions (PAO).
The Ekos Control Unit 4.0 has a color touchscreen and allows physicians to monitor and manage two Ekos devices simultaneously, the company said.
